CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
| (NASDAQ: CRVO) | Delayed: 3.18 -0.16 (4.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.34 | 52 Week High | $ | |||
| Open | $3.26 | 52 Week Low | $ | |||
| Day High | $3.36 | P/E | N/A | |||
| Day Low | $3.13 | EPS | $ | |||
| Volume | 309,462 | |||||
